A massive undertaking involving more than 1,300 scientists from 
37 countries reported in 23 papers shows the results of analyzing 47 million 
genetic changes in 2,600 genomes of 38 different tumor types. The Pan-Cancer 
Analysis of Whole Genomes (PCAWG) presented what the researchers called “the 
most comprehensive study of whole cancer genomes to date.”
Taking advantage 
of the latest sequencing and computational informatics technologies, the 
researchers, divided into 16 working groups, opened doors to the genetic 
complexities and commonalities in cancer, and offered insights that could spur 
further discoveries and eventual treatments.
PCAWG analyzed whole genomes 
rather than the more common approach of sequencing only protein-coding regions. 
They produced 1,188 tumor transcriptomes to link RNA and DNA alterations and 
explored genetic drivers, tumor signatures, and virus DNA found in cancers. 
These analyses generated more than 800 terabytes of data, roughly equivalent to 
the storage required for 200,000 movies.
PCAWG found cancer-driver mutations 
for 95% of cases, and that on average each cancer genome has four or five 
drivers. Sizable minorities of cancers showed signs of chromoplexy (17.8%) or 
chromothripsis (22.3%), reflecting complex and chaotic rearrangement processes. 
The researchers found that genetic changes leading to cancer occur early 
on—sometimes decades in advance of diagnosis.
The investigation also 
uncovered genetic drivers in noncoding DNA, like noncoding regions of the 
tumor-suppressor gene TP53 and of the telomerase gene TERT. Another PCAWG team 
characterized mutational signatures using more than 84 million somatic mutations 
from 4,645 whole-genome and 19,184 exome sequences to describe 81 signatures 
including single- doublet- and clustered-base-substitutions as well as small 
insertion-and-deletion signatures, many not previously identified. In a first, 
another team identified 16 structural variants involving large 
rearrangements.
An analysis of viruses associated with cancer highlighted the 
prevalence of Epstein–Barr virus, hepatitis B virus, and human 
papillomavirus.
All the PCAWG papers, published in Nature and related 
journals, are open access at nature.com/collections/afdejfafdb. The researchers’ 
raw genome sequencing data and other resources also are available to 
researchers.
OPIOID POISONINGS WORSENING IN CHILDREN, 
ADOLESCENTS
About one-quarter of opioid poisonings occur in children 
and adolescents, and poisoning incidents have become more severe in recent 
years, according to an abstract presented at the Society of Critical Care 
Medicine's annual congress. The retrospective study of more than 750,000 opioid 
poisoning cases reported to the National Poison Data System from 2005 to 2018 
found that 27.5% (207,543) of cases occurred in patients younger than age 
19.
Trend analysis over three eras (2005–2009, 2010–2014, and 2015–2018) 
showed that the percentage of patients admitted to critical care units and 
deaths increased over time; 6.6%, 8.5%, and 9.6% and 0.18%, 0.20%, and 0.28%, 
respectively. The probability of having a moderate or major effect also rose, by 
0.55% and 0.11%, respectively.
Opioid poisonings with the intent of 
committing suicide increased over the three time periods, from 13.9% to 
21.2%.
In a separate published report, the researchers said they observed two 
peak age distributions for opioid poisonings, in children from newborns to age 4 
and in teenagers from 15 to almost 19.
EMERGENCY DEPARTMENTS 
OVER-TEST FOR SUSPECTED PULMONARY EMBOLISM
Computed tomographic 
pulmonary angiography (CTPA) is overused in the diagnostic workup of pulmonary 
embolism (PE), underscoring “the urgent need for dissemination and 
implementation of protocols to reduce low-yield CTPA scanning,” including 
D-dimer testing, according to the authors of a study examining emergency 
department (ED) practices involving PE-related testing (Circ Cardiovasc Qual 
Outcomes 2020;13:e005753).
The study, a cross-sectional analysis of 
electronic health record and billing data from 16 EDs in Indiana and 11 
hospitals in the Dallas-Fort Worth area, identified ED patients who underwent 
any of the following, including D-dimer testing, CTPA, scintillation ventilation 
perfusion lung scanning, or pulmonary angiography. Out of 1.83 million patient 
encounters, 5.3% had a diagnostic test for PE. Nearly 60% of all patients who 
had tests for PE underwent CTPA without D-dimer testing. About 21% of CTPA took 
place in women younger than age 45, who are at greater risk of cancer from CTPA 
radiation exposure, according to the authors.
The pooled diagnostic yield of 
CTPA for PE was 3.1%, with a 1.3% rate in Indiana EDs, and a 4.8% rate in 
Dallas-Fort Worth facilities.
Patients in Indiana were less likely than those 
in Dallas-Fort Worth to receive D-dimer testing before CTPA (30% versus 52%, 
respectively), possibly reflecting the impact of a targeted quality improvement 
initiative that had taken place in Dallas-Fort Worth to increase use of D-dimer 
testing in low-risk patients.
The data imply that “D-dimer ordering 
correlates with an increased yield rate of PE on CTPA,” wrote the investigators. 
“This relationship suggests but does not prove a positive cause-effect 
relationship between rate of D-dimer ordering and PE yield.”